St. Cloud Times

Health Economic Study Shows That enVVeno Medical’s VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Results remained consistent across multiple sensitivity analyses and scenarios (different age populations, various assumptions), confirming the model’s reliability. Mark H. Meissner M.D., surgeon at ...
News Tribune

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients’ Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision ...
Modesto Bee

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study - Cash burn of $4.2 million in Q3 remains in line ...
WTNH

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision ...